Skip to main content
Journal cover image

Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.

Publication ,  Journal Article
Robertson, CN; Linehan, WM; Pass, HI; Gomella, LG; Haas, GP; Berman, A; Merino, M; Rosenberg, SA
Published in: J Urol
September 1990

A total of 63 patients with metastatic renal cell carcinoma with the primary kidney tumor in place was accepted as candidates for immunotherapy at the Surgery Branch of the National Cancer Institute. Of the 63 patients 54 underwent nephrectomy and 9 were treated with the primary kidney tumor in place. Many of the patients underwent associated procedures, such as regional lymphadenectomy (11), venacavotomy with extraction of tumor thrombus (9), hepatic resection (2), pulmonary wedge resection (2), cholecystectomy (2), splenectomy (2), distal pancreatectomy (1), omentectomy (1) and contralateral adrenalectomy (1). Of the 54 patients 20 were not able to enter therapy because of tumor-related (17) or other medical (3) reasons that developed between the operation and therapy, while 34 were able to receive immunotherapy postoperatively. The 20 patients who were treated with either high dose interleukin-2 or interleukin-2 plus lymphokine activated killer cells soon postoperatively (mean 2.1 months) were able to tolerate roughly the same amount of interleukin-2 as the 74 who had undergone nephrectomy before referral to our institute and who were treated for a mean of 22 months after nephrectomy. Further studies, including a prospective, randomized trial, will be required to define the role of nephrectomy in patients with advanced renal cell carcinoma before treatment with interleukin-2 based immunotherapies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Urol

DOI

ISSN

0022-5347

Publication Date

September 1990

Volume

144

Issue

3

Start / End Page

614 / 617

Location

United States

Related Subject Headings

  • Venae Cavae
  • Urology & Nephrology
  • Recombinant Proteins
  • Nephrectomy
  • Neoplastic Cells, Circulating
  • Middle Aged
  • Male
  • Lymph Node Excision
  • Killer Cells, Lymphokine-Activated
  • Kidney Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Robertson, C. N., Linehan, W. M., Pass, H. I., Gomella, L. G., Haas, G. P., Berman, A., … Rosenberg, S. A. (1990). Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol, 144(3), 614–617. https://doi.org/10.1016/s0022-5347(17)39537-x
Robertson, C. N., W. M. Linehan, H. I. Pass, L. G. Gomella, G. P. Haas, A. Berman, M. Merino, and S. A. Rosenberg. “Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.J Urol 144, no. 3 (September 1990): 614–17. https://doi.org/10.1016/s0022-5347(17)39537-x.
Journal cover image

Published In

J Urol

DOI

ISSN

0022-5347

Publication Date

September 1990

Volume

144

Issue

3

Start / End Page

614 / 617

Location

United States

Related Subject Headings

  • Venae Cavae
  • Urology & Nephrology
  • Recombinant Proteins
  • Nephrectomy
  • Neoplastic Cells, Circulating
  • Middle Aged
  • Male
  • Lymph Node Excision
  • Killer Cells, Lymphokine-Activated
  • Kidney Neoplasms